Gefitinib (Iressa? ): It is suitable for patients who have received chemotherapy or are not suitable for chemotherapy before the treatment of locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer).
Erotinib | Trocquer (Trocquer? ): Initial (first-line) treatment of EGFR metastatic non-small cell lung cancer (non-small cell lung cancer) and advanced pancreatic cancer (not approved in China, Trocquer)(+ Jiangyin _ Zhong Yi) was tested and confirmed by FDA-approved kit in troc quer.
Ostinib | tagris | azd9291osimertinib (tagrisso/tagrix): it is mainly used to treat advanced non-small cell lung cancer, and it is a TKI targeted drug with T790M gene mutation.
Afatinib (Gillot Reeve? ): The detection method approved by FDA is suitable for patients with metastatic non-small cell lung cancer (non-small cell lung cancer) (+Jiangyin _ Zhong Yi) with deletion mutation of exon 19 of epidermal growth factor receptor (EGFR) or substitution mutation of exon 2 1 L858R.
Sertinib | ceritinib (LDK378/Zykadia): It is suitable for the treatment of patients with non-small cell lung cancer (NSCLC), who have anaplastic lymphoblastic enzyme (ALK) positive metastasis and cannot tolerate crizotinib.
czotinib | secoricrizotinib(xal kori？ ): It can be used to treat patients with locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer) who are confirmed to be positive for ALK by CFDA-approved detection methods.
Ramorumab: second-line therapy for advanced non-small cell lung cancer after platinum chemotherapy.